Nykode Therapeutics (NYKD.OL) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

NYKD.OL · Stock Price

NOK 3.20+0.45 (+16.46%)

Market Cap: $114.3M

Historical price data

Market Cap: $114.3MPipeline: 3 drugsFounded: 2006HQ: Oslo, Norway

Sector Ranking#19 in Immunotherapy / Immuno-Oncology #99 in Biologics / Biosimilars

Overview

Nykode Therapeutics is a clinical-stage biopharma company leveraging its proprietary Vaccibody™ platform to develop targeted immunotherapies for cancer and autoimmune diseases. Founded on foundational research from the University of Oslo, the company has achieved key milestones including uplisting to the Oslo Stock Exchange and establishing high-value partnerships with Roche and Regeneron. Its strategy focuses on accelerating its internal pipeline, expanding the platform into new therapeutic areas, and forging selective strategic partnerships to maximize commercial potential.

OncologyAutoimmune DiseasesInfectious Diseases

Technology Platform

The Vaccibody™ platform is a modular immunotherapy technology engineered to specifically deliver target antigens to Antigen Presenting Cells (APCs), aiming to induce rapid, strong, and durable immune responses for treating cancer and other diseases.

Pipeline

3

3 drugs in pipeline

Drug	Indication	Stage
VB10.16 Immunotherapy (DNA vaccine)	High Grade Cervical Intraepithelial Neoplasia	Phase 1/2
VB10.2129 + VB10.2210	COVID-19	Phase 1/2
VB10.NEO	Solid Tumors, Adult	Phase 1

Funding History

3

Total raised:$212M

IPO$150MUndisclosedDec 18, 2020

Series B$52MFidelity Management & Research CompanyJun 15, 2020

Series A$10MKreos CapitalJun 15, 2017

Opportunities

The lead program VB10.16 addresses a large market in HPV-driven cancers with high unmet need for effective therapies.

The platform's modularity offers significant expansion potential into autoimmune diseases and infectious diseases, supported by high-value partnerships with Roche and Regeneron.

Risk Factors

The company faces significant clinical development risk as its value is tied to mid-stage trial outcomes.

As a pre-revenue entity, it carries funding and dilution risk for future capital needs, and operates in a highly competitive immuno-oncology landscape where technological obsolescence is a constant threat.

Competitive Landscape

Nykode competes with companies developing therapeutic cancer vaccines, including mRNA neoantigen leaders like BioNTech and Moderna, and other APC-targeting technologies. Its key differentiation is the precision targeting of its Vaccibody™ platform, aiming for potent immunogenicity with a favorable safety profile.